dc.contributorUniversidade de São Paulo (USP)
dc.contributorUniversidade Estadual Paulista (Unesp)
dc.contributorUniversidade Federal de São Carlos (UFSCar)
dc.date.accessioned2014-05-20T15:33:02Z
dc.date.accessioned2022-10-05T17:13:21Z
dc.date.available2014-05-20T15:33:02Z
dc.date.available2022-10-05T17:13:21Z
dc.date.created2014-05-20T15:33:02Z
dc.date.issued2008-02-01
dc.identifierTransplant Immunology. Amsterdam: Elsevier B.V., v. 18, n. 4, p. 361-367, 2008.
dc.identifier0966-3274
dc.identifierhttp://hdl.handle.net/11449/41781
dc.identifier10.1016/j.trim.2007.10.010
dc.identifierWOS:000252572000011
dc.identifier1768025290373669
dc.identifier0000-0003-1740-7360
dc.identifier.urihttp://repositorioslatinoamericanos.uchile.cl/handle/2250/3912670
dc.description.abstractHLA-G is a non-classic Human Leukocyte Antigen (HLA-G) Class I of low polymorphism and restricted tissue distribution that displays tolerogenic functions. In heart transplantation and in combined liver/renal allograft transplantation, the expression of HLA-G has been associated with a lower incidence of acute graft rejection episodes and absence of chronic dysfunction. Since the expression of HLA-G in renal biopsies has been investigated only in few patients who received a combined kidney and liver transplant, in this study we performed a cross-sectional study, systematically comparing the expression of HLA-G in post-transplanted renal grafts, stratifying patients according to the presence or absence of rejection.Patients and Methods: Seventy-three renal specimens (10 with acute rejection and 13 with chronic allograft nephropathy, and 50 with no signs of rejection) were immunohistochemically evaluated for HLA-G expression.Results: In the group as a whole, HLA-G molecules were detected in 40 cases (54.8%). Among specimens that presented HLA-G expression, 2 out of 40 (5%) exhibited acute rejection, 2 (5%) exhibited chronic allograft nephropathy, and the remaining 36 (90%) exhibited no signs of rejection. The comparison between patients with rejection and those without rejection showed that the expression of HLA-G was significantly increased in specimens exhibiting no signs of rejection (p<0.0001). Considering only patients with acute rejection, 8 out of 10 patients showed no HLA-G expression in their kidney biopsies when compared to patients exhibiting no signs of rejection and absence of HLA-G was observed in 14 out of 50 (p=0.0032). Similarly, considering only patients with chronic allograft nephropathy, absence of HLA-G expression was observed in I I out of 13 specimens, whereas in patients without rejection absence of HLA-G was observed in 14 out of 50 (p=0.003). Therapy with tacrolimus was significantly associated with the expression of HLA-G and a better graft prognosis. Conclusions: Our results suggest that HLA-G expression in the kidney allograft and the use of tacrolimus are associated with a lower frequency of acute renal rejection and chronic allograft nephropathy. (c) 2007 Elsevier B.V. All rights reserved.
dc.languageeng
dc.publisherElsevier B.V.
dc.relationTransplant Immunology
dc.relation1.655
dc.relation0,620
dc.rightsAcesso restrito
dc.sourceWeb of Science
dc.subjectkidney allograft
dc.subjectHLA-G
dc.subjectrejection
dc.titleHuman leukocyte antigen-G expression after kidney transplantation is associated with a reduced incidence of rejection
dc.typeArtigo


Este ítem pertenece a la siguiente institución